Literature DB >> 20937597

A classification model for G-to-A hypermutation in hepatitis B virus ultra-deep pyrosequencing reads.

Elizabeth C Reuman1, Severine Margeridon-Thermet, Harrison B Caudill, Tommy Liu, Katyna Borroto-Esoda, Evguenia S Svarovskaia, Susan P Holmes, Robert W Shafer.   

Abstract

MOTIVATION: G → A hypermutation is an innate antiviral defense mechanism, mediated by host enzymes, which leads to the mutational impairment of viruses. Sensitive and specific identification of host-mediated G → A hypermutation is a novel sequence analysis challenge, particularly for viral deep sequencing studies. For example, two of the most common hepatitis B virus (HBV) reverse transcriptase (RT) drug-resistance mutations, A181T and M204I, arise from G → A changes and are routinely detected as low-abundance variants in nearly all HBV deep sequencing samples.
RESULTS: We developed a classification model using measures of G → A excess and predicted indicators of lethal mutation and applied this model to 325 920 unique deep sequencing reads from plasma virus samples from 45 drug treatment-naïve HBV-infected individuals. The 2.9% of sequence reads that were classified as hypermutated by our model included most of the reads with A181T and/or M204I, indicating the usefulness of this model for distinguishing viral adaptive changes from host-mediated viral editing. AVAILABILITY: Source code and sequence data are available at http://hivdb.stanford.edu/pages/resources.html. CONTACT: ereuman@stanfordalumni.org SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20937597      PMCID: PMC2982158          DOI: 10.1093/bioinformatics/btq570

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  19 in total

Review 1.  Covering all bases in HIV research: unveiling a hidden world of viral evolution.

Authors:  Bram Vrancken; Sébastian Lequime; Kristof Theys; Philippe Lemey
Journal:  AIDS Rev       Date:  2010 Apr-Jun       Impact factor: 2.500

Review 2.  Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.

Authors:  Bryan R Cullen
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  HyperPack: a software package for the study of levels, contexts, and patterns of APOBEC-mediated hypermutation in HIV.

Authors:  Gustavo H Kijak; Mario Janini; Sodsai Tovanabutra; Eric E Sanders-Buell; Debora L Birx; Merlin L Robb; Nelson L Michael; Francine E McCutchan
Journal:  AIDS Res Hum Retroviruses       Date:  2007-04       Impact factor: 2.205

Review 4.  Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.

Authors:  Anna S Lok; Fabien Zoulim; Stephen Locarnini; Angeline Bartholomeusz; Marc G Ghany; Jean-Michel Pawlotsky; Yun-Fan Liaw; Masashi Mizokami; Carla Kuiken
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

5.  G to A hypermutation of hepatitis B virus.

Authors:  Chiemi Noguchi; Hiromi Ishino; Masataka Tsuge; Yoshifumi Fujimoto; Michio Imamura; Shoichi Takahashi; Kazuaki Chayama
Journal:  Hepatology       Date:  2005-03       Impact factor: 17.425

6.  Hepatitis B virus genomes from long-term immunosuppressed virus carriers are modified by specific mutations in several regions.

Authors:  Petra Preikschat; Helga Meisel; Hans Will; Stephan Günther
Journal:  J Gen Virol       Date:  1999-10       Impact factor: 3.891

7.  A revised evolutionary history of hepatitis B virus (HBV).

Authors:  Mario Ali Fares; Edward C Holmes
Journal:  J Mol Evol       Date:  2002-06       Impact factor: 2.395

8.  Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo.

Authors:  Rodolphe Suspène; Denise Guétard; Michel Henry; Peter Sommer; Simon Wain-Hobson; Jean-Pierre Vartanian
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-26       Impact factor: 11.205

9.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

10.  A web-based genotyping resource for viral sequences.

Authors:  Mikhail Rozanov; Uwe Plikat; Colombe Chappey; Andrey Kochergin; Tatiana Tatusova
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

View more
  6 in total

Review 1.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

2.  Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.

Authors:  Severine Margeridon-Thermet; Evguenia S Svarovskaia; Farbod Babrzadeh; Ross Martin; Tommy F Liu; Mary Pacold; Elizabeth C Reuman; Susan P Holmes; Katyna Borroto-Esoda; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

Review 3.  Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach.

Authors:  Francisco Rodriguez-Frias; Maria Buti; David Tabernero; Maria Homs
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

4.  Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data.

Authors:  Niko Beerenwinkel; Huldrych F Günthard; Volker Roth; Karin J Metzner
Journal:  Front Microbiol       Date:  2012-09-11       Impact factor: 5.640

5.  Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.

Authors:  Severine Margeridon-Thermet; Robert W Shafer
Journal:  Viruses       Date:  2010-12-01       Impact factor: 5.048

6.  Prevalence of genotypes and subtypes of hepatitis B viruses in Bangladeshi population.

Authors:  Md Arifur Rahman; Farzana Hakim; Mamun Ahmed; Chowdhury Rafiqul Ahsan; Jamalun Nessa; Mahmuda Yasmin
Journal:  Springerplus       Date:  2016-03-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.